Inflection: Pairing up PIM

Inflection combines pan-PIM kinase, PI3K, mTOR inhibitors in single molecule

Inflection Biosciences Ltd. is developing pan-PIM kinase inhibitors that are a few years behind large pharma competitors, but the biotech's compounds can be structurally linked to other kinase inhibitors for cancer. The small molecules thus could address multiple pathways with a single compound, simplifying combination therapy.

PIM kinases are a family of serine threonine kinases involved in cell cycle regulation, apoptosis,

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers